Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited
Cardiovascular Ultrasound

Application value of echocardiography in pre-procedure evaluation and post-procedure follow-up in transcatheter aortic valve replacement

  • Chunqiang Hu 1 ,
  • Wei Li 1 ,
  • Weipeng Zhao 1 ,
  • Zhenyi Ge 1 ,
  • Daxin Zhou 2 ,
  • Wenzhi Pan 2, ,
  • Xianhong Shu 1 ,
  • Cuizhen Pan , 1
Expand
  • 1.Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai Institute of Medical Imaging, Shanghai 200032, China
  • 2.Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai Institute of Medical Imaging, Shanghai 200032, China
Corresponding author: Pan Cuizhen, Email: pan.cuizhen@zs-hospital.sh.cn

Received date: 2021-05-29

  Online published: 2021-11-02

Copyright

Copyright by Chinese Medical Association No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission. All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.

Abstract

Objective

To assess the value of echocardiography in evaluating the cardiac structure and function before and after transcatheter aortic valve replacement (TAVR).

Methods

A total of 47 patients with severe aortic valve stenosis (SAS) who underwent TAVR at the Department of Cardiology, Zhongshan Hospital of Fudan University from September 2014 to July 2019 were retrospectively enrolled. All patients received echocardiography before and 6 months after TAVR, and conventional echocardiography parameters and aortic valve-related parameters were routine recorded. Echocardiographic parameters, including left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), interventricular septum thickness (IVST), left ventricular posterior wall thickness (PWT), pulmonary artery systolic pressure (PASP), maximum aortic valve pressure gradient (AVPGmax), mean aortic valve pressure gradient (AVPGmean), aortic valve effective orifice area (AVA), left ventricular ejection fraction (LVEF), aortic root diameter (AORD), and left atrial diameter (LAD) were collected, and left ventricular mass index was calculated according to LVEDD, IVST, and PWT. The changes of TAVR echocardiographic parameters pre- and post-procedure were analyzed.

Results

Compared with the values on admission, LVESD, IVST, PWT, PASP, AVPGmax, and AVPGmean at follow-up were significantly decreased in the patients (P<0.05). Both AVA and LVEF significantly increased (P<0.05). The number of cases with moderate or above mitral regurgitation and tricuspid regurgitation decreased significantly post-procedure (8 vs 3, 7 vs 2).

Conclusion

TAVR can correct aortic stenosis (AS) and improve cardiac function. Echocardiography plays a crucial role in evaluating the cardiac construction and function and the prosthesis after TAVR.

Cite this article

Chunqiang Hu , Wei Li , Weipeng Zhao , Zhenyi Ge , Daxin Zhou , Wenzhi Pan , Xianhong Shu , Cuizhen Pan . Application value of echocardiography in pre-procedure evaluation and post-procedure follow-up in transcatheter aortic valve replacement[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2021 , 18(10) : 948 -953 . DOI: 10.3877/cma.j.issn.1672-6448.2021.10.009

自2002年报道首例人体经导管置换主动脉瓣膜以来,经导管主动脉瓣置换(transcatheter aortic valve replacement,TAVR)成为外科手术高危或中危的重度主动脉瓣狭窄(severe aortic valve stenosis,SAS)患者的常规治疗策略1, 2, 3。且多项最新研究证实了TAVR在更低危、更年轻及二叶式主动脉瓣患者中开展的可行性及安全性4, 5, 6, 7, 8。TAVR作为一项需多学科合作的技术,超声心动图检查在选择具有TAVR适应证的患者、确定个体化的手术方案和时机、完善术中监护及临床预后评估中发挥着不可或缺的作用。本研究应用二维超声心动图评估TAVR术后患者的早期预后,探索超声心动图参数在TAVR术前评估及术后随访中的应用价值。

资料与方法

一、对象

回顾性选取2014年9月至2019年7月在复旦大学附属中山医院心内科行TAVR的SAS患者47例,其中男性32例,女性15例,年龄59~88(79.9±5.2)岁。纳入标准为:(1)SAS:超声心动图示主动脉瓣峰值血流速度(maximun aortic valve orifice blood flow velocity,Vmax)≥4.0 m/s,或主动脉瓣平均跨瓣压差(mean aortic valve pressure gradient,AVPGmean)≥40 mmHg(1 mmHg=0.133 kPa),或主动脉瓣有效瓣口面积(aortic valve area,AVA)<1.0 cm2。(2)美国纽约心脏病协会(New York Heart Association,NYHA)心功能分级Ⅱ级以上,且明确为主动脉瓣狭窄(aortic stenosis,AS)所致。(3)影像学检查明确主动脉根部及周围血管解剖适合行TAVR。(4)不适宜外科手术的高风险患者经多学科心脏团队评估后决定行TAVR。排除标准为:(1)纠正AS后预期生存时间<12个月。(2)有TAVR手术禁忌证:左心室内血栓、左心室流出道梗阻等。(3)左心衰竭或其他脏器衰竭者。(4)超声心动图图像质量差。本研究获复旦大学附属中山医院医学伦理委员会审批通过。

二、仪器与方法

1. 仪器:采用Philips iE33或Philips EPIQ 7C型超声诊断仪,使用S5-1探头(经胸探头),X7-2t探头或X8-2t探头(经食管探头),频率为1~5 MHz,2~7 MHz或2~8 MHz。
2. 临床资料:收集并记录患者的临床资料,包括性别、年龄、并发疾病(如高血压、糖尿病、高脂血症、冠心病、肾功能不全、慢性阻塞性肺疾病)、NYHA心功能分级及既往心脏手术史。
3. TAVR:(1)手术过程:所有操作均于心导管室在经食管超声心电图、数字剪影血管造影(digital subtraction angiography,DSA)引导下完成。结合术前多层螺旋CT(multisliecs helieal computed tomography,MSCT)及超声心动图测量的瓣环直径,装配好合适型号的人工瓣膜。经加硬导丝送入装备好瓣膜的导管输送系统至主动脉瓣环处,在主动脉根部造影及右心室快速起搏(频率120~150次/分,起搏时间10~20 s)的协助下释放瓣膜,术后即刻行经食管超声心动图评估人工主动脉瓣定位及瓣周漏(perivalve leakage,PVL)情况。(2)手术效果:术中无需转外科开胸或术后30 d内未出现人工瓣膜移位或脱落、中度及以上PVL、冠状动脉阻塞或未植入永久起搏器定义为临床成功。
4. 二维超声心动图图像采集和数据测量:所有患者均于术前及术后6个月行经胸超声心动图检查并记录检查数据,包括常规超声心动图参数,如主动脉根部内径(aortic root diameter,AORD)即主动脉窦部宽度、左心房内径(left atria diameter,LAD)、左心室舒张末期内径(left ventricular end-diastolic diameter,LVEDD)、左心室收缩末期内径(left ventricular end-systolic diameter,LVESD)、室间隔厚度(interventricular septum thickness,IVST)、左心室后壁厚度(posterior wall thickness,PWT)、肺动脉收缩压(pulmonary artery systolic pressure,PASP)、左心室射血分数(left ventricular ejection fractions,LVEF);主动脉瓣相关参数,如AVA、Vmax、主动脉瓣最大跨瓣压差(maximun aortic valve pressure gradient,AVPGmax)、AVPGmean及PVL情况(图1)。
图1 重度主动脉瓣狭窄患者经导管主动脉瓣置换(TAVR)术前与术后6个月随访超声心动图图像。图a~d为术前超声图像,其中图a为胸骨旁左心室长轴切面测量主动脉根部解剖结构,可显示左心室流出道、主动脉瓣环、主动脉窦部、窦管交界处、升主动脉(图中AA为主动脉瓣环,AoS为主动脉窦部,STJ为窦管交界处,AAO为升主动脉);图b,c为心尖五腔心切面勾勒左心室流出道、主动脉瓣口频谱多普勒,获得速度时间积分及主动脉瓣相关参数;图d为心尖五腔心切面彩色多普勒显示重度二尖瓣反流。图e~h为术后6个月超声图像,其中图e为胸骨旁左心室长轴切面显示人工生物主动脉瓣位置固定;图f根据连续方程法估算人工主动脉瓣有效瓣口面积为2.15 cm2;图g示主动脉瓣平均跨瓣压差(AVPGmean)从术前的88 mmHg(1 mmHg=0.133 kPa)降至术后的8 mmHg;图h为彩色多普勒显示重度二尖瓣反流术后转为轻度二尖瓣反流
5. 三维经食管超声心动图(three-dimensional transesophageal echocardiography,3D-TEE)图像获取及分析:(1)图像获取:术中患者全身麻醉后,将探头缓慢插入食管,记录食管中段长轴、短轴及五腔观和食管上段长轴和短轴观二维、三维超声参数。然后将采集的资料储存到光盘,进行在机或脱机分析。(2)3D-TEE主动脉瓣环测量:取标准左心室长轴观,在ZOOM模式下采集主动脉瓣环的三维图像,并应用QLAB-3DQ软件定量主动脉瓣环的最大径、最小径、面积(图2)。
图2 QLAB-3DQ软件定量主动脉瓣环的最大径、最小径、面积
6. PVL、二尖瓣反流、三尖瓣反流的超声心动图评估9, 10, 11:(1)PVL程度:根据人工瓣膜短轴切面仔细观察反流颈判断圆周范围的反流程度,PVL<10%瓣环周长为轻度,10%~29%为中度,≥30%为重度。如人工瓣膜出现摆动现象,则表明>40%的瓣环出现撕裂,或者通过反流束宽度(占左心室流出道内径的百分比)来判定,窄小(≤25%)为轻度,26%~64%为中度,宽大(≥65%)为重度。(2)二尖瓣反流程度:主要根据彩色多普勒方法半定量及定量(反流束面积、缩流颈宽度、近端等速表面积)评估。(3)三尖瓣反流程度:主要根据反流束面积、缩流颈宽度和肝静脉血流图来评估。

三、统计学分析

使用SPSS 25.0统计软件对数据进行统计分析。本研究超声心动图参数均为符合正态分布的计量资料,以
x¯
±s表示,术前与术后比较采用配对t检验。3D-TEE与MSCT术前评估主动脉根部结构比较采用独立样本t检验。计数资料以例(%)表示,术前与术后比较采用卡方检验,以P<0.05为差异有统计学意义。

结果

一、一般资料及手术情况

1. 一般资料:47例接受TAVR的SAS患者中,三叶式主动脉瓣28例,二叶式主动脉瓣19例。SAS并中度及以上主动脉瓣反流者14例(14/47,29.8%),NYHA心功能分级Ⅲ级及以上者29例(29/47,61.7%),中度及以上二尖瓣反流8例(8/47,17.2%),中度及以上三尖瓣反流7例(7/47,14.9%),中度及以上主动脉瓣反流14例(14/47,29.8%)。
2. 手术情况:47例行TAVR的患者均为经股动脉途径,16例植入Venus A-Vavle瓣膜,31例植入VitaFlow瓣膜,手术成功39例。7例于术后1周内出现Ⅲ度房室传导阻滞而行永久起搏器植入术;1例出现瓣膜移位导致机械性冠状动脉闭塞而行冠状动脉搭桥术。47例患者均未出现中度及以上PVL。

二、3D-TEE与MSCT对术前主动脉根部解剖结构的评估

3D-TEE与MSCT在术前主动脉瓣环最大径、最小径、瓣环面积以及AVA的测值上差异均无统计学意义(P均<0.05,表1)。
表1 3D-TEE与MSCT术前评估主动脉根部结构比较(
x¯
±s
参数 3D-TEE MSCT t P
主动脉瓣环

最大径(cm)

26.1±2.08 26.2±2.4 -0.12 0.901

最小径(cm)

21.2±2.04 21.1±2.06 0.12 0.902

面积(cm2

425.8±70.23 418.5±68.65 0.41 0.681
AVA(cm2 62.3±13.84 61.6±18.66 0.17 0.869

注:3D-TEE为三维经食管超声心动图;MSCT为多层螺旋CT;AVA为主动脉瓣有效瓣口面积

三、TAVR术前与术后6个月超声心动图参数比较

与术前相比,术后47例患者的LVESD、IVST、PWT、PASP、AVPGmax、AVPGmean、Vmax均明显减小,差异均有统计学意义(P均<0.05);AVA和LVEF均明显增大,差异均有统计学意义(P均<0.05);AORD、LAD、LVEDD术前与术后6个月比较,差异均无统计学意义(P均>0.05)。术后合并中度及以上二尖瓣反流或中度及以上三尖瓣反流的患者较术前明显减少(8例vs 3例,7例vs 2例,表23)。术后11例患者无三尖瓣反流,PASP无法通过心尖四腔心三尖瓣反流处频谱多普勒测得。
表2 TAVR术前与术后6个月超声心动图常规参数比较
参数 术前(n=47) 术后6个月(n=47) 统计值 P
AORD(mm,
x¯
±s
32.6±4.32 32.0±4.53 t=0.57 0.572
LAD(mm,
x¯
±s
43.9±6.46 42.1±7.51 t=1.23 0.226
LVEDD(mm,
x¯
±s
49.7±7.94 46.9±6.14 t=1.93 0.059
LVESD(mm,
x¯
±s
34.8±9.40 30.2±6.11 t=3.04 0.004
IVST(mm,
x¯
±s
13.3±1.98 12.1±1.93 t=2.72 0.009
PWT(mm,
x¯
±s
12.2±1.24 11.1±1.45 t=4.13 <0.001
PASP(mmHg,
x¯
±s
47.3±14.48 38.6±8.70 t=3.27 0.002
LVEF(%,
x¯
±s
57±12.4 64±8.3 t=-3.36 0.002
MR中度及以上[例(%)] 8(17) 3(6) χ2=2.57 0.109
TR中度及以上[例(%)] 7(15) 2(4) χ2=1.97 0.161
AR中度及以上[例(%)] 14(30) 0 χ2=16.45 <0.001

注:1 mmHg=0.133 kPa;TAVR为经导管主动脉瓣置换;AORD为主动脉根部内径;LAD为左心房内径;LVEDD为左心室舒张末期内径;LVESD为左心室收缩末期内径;IVST为室间隔厚度;PWT为左心室后壁厚度;PASP为肺动脉收缩压;LVEF为左心室射血分数;MR为二尖瓣反流;TR为三尖瓣反流;AR为主动脉瓣反流

表3 TAVR术前与术后6个月主动脉瓣相关超声心动图参数比较(
x¯
±s
参数 术前(n=47) 术后6个月(n=47) t P
AVPGmax(mmHg) 102±31.3 21±7.7 17.14 <0.001
AVPGmean(mmHg) 59±18.5 11±4.3 16.65 <0.001
AVA(cm2 0.67±0.16 1.8±0.24 -24.50 <0.001
Vmax(m/s) 4.96±0.71 2.26±0.42 21.53 <0.001

注:1 mmHg=0.133 kPa;TAVR为经导管主动脉瓣置换;AVPGmax为主动脉瓣最大跨瓣压差;AVPGmean为主动脉瓣平均跨瓣压差;AVA为主动脉瓣有效瓣口面积;Vmax为主动脉瓣峰值血流速度

讨论

自3款国产人工主动脉瓣膜(Venus-A、J-Valve及VitaFlow)上市以来,我国TAVR治疗SAS的进展迅速,有经验的中心也逐渐拓宽TAVR的适应证,在更低危、更年轻及二叶式主动脉瓣患者人群中开展TAVR4, 5, 6, 7, 8。TAVR技术蓬勃发展的同时也离不开超声心动图在TAVR中发挥的重要作用。本研究结果显示:TAVR手术安全有效,能显著降低患者AVPGmean和Vmax,提高AVA,纠正SAS;术后6个月患者左心室逆重构及收缩功能得到改善。超声心动图相关参数有助于TAVR术后人工瓣膜及患者心脏结构功能的随访评估。
SAS主要引起左心室阻力负荷增加,室壁向心性肥厚,心室扩张,失代偿后出现心力衰竭。TAVR将人工主动脉瓣经导管置入到病变的主动脉瓣处,替代主动脉瓣的功能。TAVR纠正SAS后,APVGmean明显降低致使阻力负荷降低,许多研究也发现TAVR术后LVEF得到改善12, 13, 14。Jilaihawi等15研究AS患者TAVR术后早期左心室壁厚度的改变,结果显示室间隔厚度较术前减小13%。LVEF升高及左心室壁厚度的变薄符合左心室逆重构的改变。肖明虎等16在对113例行TAVR的SAS患者进行随访研究中发现,对比术前与术后1年左心室大小、左心室壁厚度以及左心室功能的变化,TAVR术后1年左心室发生明显逆重构,左心室内径变小,左心室壁厚度变薄,LVEF增加,与本研究结果一致。
据研究报道,TAVR术后超过50%的患者会出现中度或重度PVL,且伴有中、重度PVL的TAVR术后患者住院死亡率增加17, 18, 19。本研究47例TAVR术后患者均未出现由于瓣膜贴合不良导致的中度或重度PVL,这可能与以下两点原因有关:(1)术前MSCT与超声心动图精确评估主动脉根部解剖结构(如AORD、主动脉瓣环内径)为临床提供了准确依据,手术均选择最适合患者主动脉根部结构的人工主动脉瓣型号;(2)两款国产自膨式人工主动脉瓣独特的裙边设计,有效减少了PVL。虽然严重影响预后的PVL未出现,但是中度以下PVL却很常见,本研究有32例(68%)术后出现中度以下PVL。本研究因房室传导阻滞而行永久起搏器植入术的有7例(15%),这与相关研究报道的17%结果相近。
本研究存在以下局限性:(1)样本量较小且随访时间较短,未来仍需扩大样本量并延长随访时间来证实本研究结果;(2)本研究术后未对患者进行MSCT检查,有待进一步行术后MDCT,并结合超声心动图检查联合评价TAVR术前与术后人工主动脉瓣及心脏结构和功能的变化。
综上所述,本研究应用超声心动图评估SAS患者TAVR术前及术后的人工瓣膜及心脏结构功能情况,结果显示,TAVR手术安全有效,可显著改善患者心功能。超声心动图参数(如PWT、IVST、LVEF、AVPGmax、AVPGmean、AVA、Vmax)有助于TAVR术后评估人工瓣膜及心脏结构功能。依据本中心既往TAVR术后随访经验,AVPGmean<20 mmHg及PVL中度以下是评估TAVR术后预后良好的重要观察指标,今后仍需开展进一步研究验证相关结论。
1
Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description [J]. Circulation, 2002, 106(24): 3006-3008.

2
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines [J]. J Am Coll Cardiol, 2017, 70(2): 252-289.

3
Otto CM, Kumbhani DJ, Alexander KP, et al. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology task force on clinical expert consensus documents [J]. J Am Coll Cardiol, 2017, 69(10): 1313-1346.

4
Frerker C, Baldus S, Nitschmann S. Transcatheter aortic valve replacement: PARTNER 3 trial and Evolut Low Risk Trial [J]. Internist (Berl), 2019, 60(11): 1221-1224.

5
Liu XB, Jiang JB, Zhou QJ, et al. Evaluation of the safety and efficacy of transcatheter aortic valve implantation in patients with a severe stenotic bicuspid aortic valve in a Chinese population [J]. J Zhejiang Univ Sci B, 2015, 16(3): 208-214.

6
Liao YB, Li YJ, Xiong TY, et al. Comparison of procedural, clinical and valve performance results of transcatheter aortic valve replacement in patients with bicuspid versus tricuspid aortic stenosis [J]. Int J Cardiol, 2018, 254: 69-74.

7
Zhou D, Pan W, Wang J, et al. VitaFlow™ transcatheter valve system in the treatment of severe aortic stenosis: one-year results of a multicenter study [J]. Catheter Cardiovasc Interv, 2020, 95(2): 332-338.

8
宋光远, 王墨扬, 王媛, 等. Venus-A主动脉瓣膜介入治疗重度主动脉瓣狭窄的效果 [J]. 中华心血管病杂志, 2017, 45(10): 843-847.

9
Hoffmeister KJ, Henderson ZT, Hussey PT, et al. Guidelines for the evaluation of valvular regurgitation after percutaneous valve repair or replacement: a focused review for the cardiac anesthesiologist [J]. J Cardiothorac Vasc Anesth, 2020, 34(10): 2740-2753.

10
Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation [J]. J Am Soc Echocardiogr, 2017, 30(4): 303-371.

11
Zoghbi WA, Asch FM, Bruce C, et al. Guidelines for the evaluation of valvular regurgitation after percutaneous valve repair or replacement [J]. J Am Soc Echocardiogr, 2019, 32(4): 431-475.

12
Ayhan H, Kasapkara HA, Durmazt , et al. Impact of transcatheter aortic valve implantation in patients with reduced ejection fraction [J]. Cardiol J, 2015, 22(1): 108-114.

13
Cribier A, Eltchaninoff H, Tron C, et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis [J]. J Am Coll Cardiol, 2004, 43(4): 698-703.

14
赵映, 李治安, 孙琳, 等. 斑点追踪技术评价重度主动脉瓣狭窄瓣膜置换术前后左室收缩功能 [J]. 中国超声医学杂志, 2011, 27(3): 224-227.

15
Jilaihawi H, Jeilan M, Spyt T, et al. Early regression of left ventricular wall thickness following percutaneous aortic valve replacement with the CoreValve bioprosthesis [J]. J Invasive Cardiol, 2009, 21(4): 151-155.

16
肖明虎, 吴永健, 王婧金, 等. 经导管主动脉瓣置换术后左心室的逆重构 [J]. 中国超声医学杂志, 2019, 35(11): 998-1000.

17
Webb JG, Altwegg L, Boone RH, et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes [J]. Circulation, 2009, 119(23): 3009-3016.

18
Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement [J]. N Engl J Med, 2012, 366(18): 1686-1695.

19
Abdel-Wahab M, Zahn R, Horack M, et al. Aortic regurgitation after transcatheter aortic valve implantation: incidence and early outcome. Results from the German transcatheter aortic valve interventions registry [J]. Heart, 2011, 97(11): 899-906.

Outlines

/

Copyright © Chinese Journal of Medical Ultrasound (Electronic Edition), All Rights Reserved.
Tel: 010-51322630、2632、2628 Fax: 010-51322630 E-mail: csbjb@cma.org.cn
Powered by Beijing Magtech Co. Ltd